US OptionsDetailed Quotes

CTMX250117C1000

Watchlist

0.20
0.000.00%

15min DelayClose Dec 24 13:00 ET

0.00High0.00Low

CytomX Stock Discussion

Trytosaveabit

Dec 3 06:01

Watching for data outadis!

$CytomX (CTMX.US)$ CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference! December 4 at 8AM est!

🔴WATCHLIST Tuesday 12/3. NFA. Don’t open position without momentum. Use charts+indicators+order book. NO FOMO.

Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...

Stock_Drift

Dec 2 15:45

After Hours Ticks 5:44pm 12/2

$CytomX (CTMX.US)$ $Onconetix (ONCO.US)$ $Edesa Biotech (EDSA.US)$ $XBP Europe Holdings (XBP.US)$ $Nauticus Robotics (KITT.US)$ $Alset (AEI.US)$ $Carmell (CTCX.US)$ $Jayud Global Logistics Ltd. (JYD.US)$ $Vir Biotechnology (VIR.US)$ $Shimmick (SHIM.US)$ $Credo Technology (CRDO.US)$ $Janux Therapeutics (JANX.US)$ $Citius Oncology (CTOR.US)$ $Volato Group (SOAR.US)$
📊⚡️📊

Iwill TradeScared

Nov 8 13:17

$CytomX (CTMX.US)$ no more 8X 💵 stock got to be extra cautious before buying glad I didn’t jumped in still negative free cash flow no risk will be taken whatever price target from fake gurus of street

Iwill TradeScared

Oct 11 00:26

$CytomX (CTMX.US)$ might be 8 Xbagger you never know 🤷🏻‍♂️

Jaguar8

Sep 9 07:02

NEWS

$CytomX (CTMX.US)$
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

102979232

Jul 12 18:47

$CytomX (CTMX.US)$ Volumn is very low but rising slowly. Interesting

amiable Hedgehog_758

May 13 05:27

$CytomX (CTMX.US)$ what is going on with this stock amy one know ?

Stock Region

May 9 13:31

Therapeutics Company Reveals Positive Data From Cancer Clinical Study

CX-904 showcased a favorable safety profile, a critical factor in the administration and monitoring of patients in outpatient settings.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...

No comment yet